Edaravone: A new drug approved for ALS

Cell
Jeffrey D Rothstein

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

Citations

Feb 1, 2018·International Journal of Molecular Sciences·Svitlana Garbuzova-DavisCesario V Borlongan
Jan 18, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Francisco Espejo-PorrasEva de Lago
Sep 19, 2018·Free Radical Research·Paul R J AmesJose DelgadoAlves
Oct 6, 2018·Journal of Biomolecular Structure & Dynamics·Ramu ManjulaBalasundaram Padmanabhan
May 12, 2019·British Journal of Pharmacology·Radha Desai, Michelangelo Campanella
Mar 25, 2020·Cell Transplantation·Svitlana Garbuzova-DavisCesario V Borlongan
Apr 26, 2020·International Journal of Molecular Sciences·Agata Grazia D'AmicoVelia D'Agata
Jan 4, 2020·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Beata Chełstowska, Magdalena Kuźma-Kozakiewicz
May 31, 2020·International Journal of Molecular Sciences·Yeomin Yun, Yoon Ha
Jul 21, 2020·Medicinal Research Reviews·Elena F ShevtsovaSergey O Bachurin
May 31, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Isra' ZeiadehRafik Karaman
Mar 3, 2020·Frontiers in Physiology·Sandra Carrera-JuliáEraci Drehmer
Jun 20, 2020·Journal of Cellular and Molecular Medicine·Chunyu LiHuifang Shang
Apr 11, 2018·Antioxidants & Redox Signaling·Juan I SbodioBindu D Paul
Aug 31, 2018·Acta Neuropathologica Communications·L McGurkN M Bonini
Apr 28, 2018·International Journal of Molecular Sciences·Anna SobuśBogusław Machaliński
Jul 20, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Zichun ZhaoZhenzhong Li
Apr 11, 2018·Oxidative Medicine and Cellular Longevity·Nicholas E BuglakEdward S M Bahnson
Aug 7, 2019·Disease Models & Mechanisms·Martin CrivelloJochen H M Prehn
Feb 23, 2020·Frontiers in Neuroscience·Frances TheunissenPatrick Anthony Akkari
Aug 31, 2020·PeerJ·Greta MusteikyteVytautas Smirnovas
Mar 3, 2020·Frontiers in Neuroscience·Yevgeniya A AbramzonRuth Chia
Oct 20, 2020·Journal of Neuromuscular Diseases·Marisa CappellaMaria Grazia Biferi
Dec 29, 2020·Neuroscience and Biobehavioral Reviews·Regine Sitruk-WareCesar V Borlongan
Jan 10, 2020·Neuroscience and Biobehavioral Reviews·Jéssica Paloma Rosa SilvaDeise Maria Furtado de Mendonça
Jan 20, 2021·Current Opinion in Structural Biology·Esther S Choi, Nikolay V Dokholyan
Feb 23, 2021·Journal of Medicinal Chemistry·Dean G Brown, Heike J Wobst
Apr 13, 2021·Neuropharmacology·Samuel S DuffyGila Moalem-Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Researcher Network:CZI Neurodegeneration Challenge

The Neurodegeneration Challenge Network aims to provide funding for and to bring together researchers studying neurodegenerative diseases. Find the latest research from the NDCN grantees here.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Cell eTOC

Cell is a scientific journal publishing research across a broad range of disciplines within the life sciences field. Discover the latest research from Cell here.

Related Papers

The New England Journal of Medicine
R S Burgerman
The New England Journal of Medicine
K D McRae
The New England Journal of Medicine
M A Rogawski
The New England Journal of Medicine
J R Murphy
© 2022 Meta ULC. All rights reserved